Arca
Skip to content
Tools
Tools

Cardiac sudden death

Drug research and approvals for cardiac sudden death: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 65 studies of cardiac sudden death are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 65
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 65 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 12

Phase 2 10

Phase 1 or earlier 1

How its trials ended

276 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 48 whose ending is known, 44% met their primary endpoint, 15% missed it and 42% stopped early.

  • Completed, result not reported11642%
  • Ongoing6022%
  • Status unknown5219%
  • Met its primary endpoint218%
  • Stopped: other or unclear93%
  • Missed its primary endpoint73%
  • Stopped: enrollment or feasibility73%
  • Stopped: funding31%
  • Stopped: lack of efficacy1<1%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.